

November 05, 2018

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip code: 512529

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051
Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Copy of Advertisement Published in Newspaper

Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed copies of advertisement published in Business Standard newspaper earlier in the day providing snapshot of Results of the Company for the quarter ended September 30, 2018.

Kindly take the same in your record.

Thanking you,

Yours faithfully,

For Sequent Scientific Limited



Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India
Tel.: +91-22-41114777 | **Fax:** +91-22-41114754 | **CIN:** L99999MH1985PLC036685
<http://www.sequent.in>

Business Standard

MUMBAI | MONDAY, 5 NOVEMBER 2018



SeQuent Scientific Limited

India's Largest Animal Health Company



Annualised
EPS at INR 2.4

Revenues up by

27%



EBITDA up by

68%



Net Profit up by

4x



API Business
grew **40%**



14 API filings
in **US** (Highest
in Industry)

Unaudited Financial Results for the Quarter ended September 30, 2018

Values in INR Mn	Q2FY19	Q2FY18	Growth
Revenues	2,517	1,975	27%
EBITDA	320	190	68%
EBITDA Margin	12.7%	9.6%	310bps
Net Profit	152	29	425%
Net Margin	6.1%	1.5%	460bps

Note: Detailed financial result is available on stock exchange websites and company website

